Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short descriptor: Ciltacabtagene car-pos t
Look up Q2056 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
Q2056 is the HCPCS Level II code for Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (2026). It belongs to Section Q — Temporary Codes. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Drugs.
Classification & CMS Attributes
- Section
- Q: Temporary Codes
- Medicare Coverage
- Carrier judgment (code C)
- Part B Pricing
- Drugs (indicator 51)
- Type of Service
- Medical care
- Effective Date
- 2022-10-01
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference Q2056 with the canonical source and edition:
Q2056 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/Q2056
Canonical URL: https://icd10codingpro.com/hcpcs-codes/Q2056